《藍籌業績》石藥(01093.HK)首三季純利43.35億人幣升23.2%
石藥集團(01093.HK)公佈截至今年9月底止首三季業績,營業額206.42億元人民幣(下同),按年升7.4%。純利43.35億元,按年升23.2%;每股盈利36.26分。
其中,成藥業務於本期錄得收入168.02億元,按年增6.9%,維生素C產品於本期錄得銷售收入升12.4%至16.17億元,抗生素及其它產品的銷售收入增24%至12.35億元,功能食品及其它業務收入跌7.5%至9.88億元。
公司指,本期的研發費用達25.08億元,按年增10.7%,目前在研項目約300項,其中小分子創新藥40餘項、大分子創新藥40餘項,新型製劑藥品30餘項,主要聚焦於抗腫瘤、免疫及呼吸、精神神經、代謝、心腦血管系統及抗感染的治療領域。未來五年,集團預計將有30餘個創新藥及新型製劑產品,以及60餘個仿製藥上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.